Advertisement

Topics

Search Results for "Where To Buy Pirfenidone"

11:50 EDT 17th August 2017 | BioPortfolio

Matching Channels

None

Matching News

New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)

Roche today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International C...

New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Socie...

Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, Revision: 17, Authorised

NICE continues to deny patients with early IPF access to pirfenidone

The National Institute for Health and Care Excellence (NICE) has stuck by its recommendation, made last…

Pirfenidone and Nintedanib for Idiopathic Pulmonary Fibrosis

Until recently, there was no effective treatment for idiopathic pulmonary fibrosis, but two new agents were approved in 2014. How do these drugs impact outcomes in this often-fatal disease? Southern...

Immediate-release formulation means fewer pills and more flexibility, says Roche

The European Medicines Agency has approved a new tablet formulation of Esbriet (pirfenidone), which Roche says reduces pill-load and increases dosing flexibility for patients with a rare lung disease.

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team

Genoa Pharmaceuticals, Inc., a biopharmaceutical company focused on development of improved therapies for idiopathic pulmonary fibrosis (IPF) and other severe pulmonary indication...

New data at ATS add to the body of evidence for Roche's Esbriet in idiopathic pulmonary fibrosis

Roche has announced new retrospective data analyses for Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International Confe...

Matching PubMed Articles

Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.

PurposeThe purpose of the study was to evaluate the efficacy and safety of intravitreal pirfenidone for inhibition of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.Pati...

A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone: Inhibition of Collagen Fibril Assembly.

Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of extracellular matrix, in particular collagens. Two IPF therapeutics, nintedanib and pirfenidone, decelerate lung functio...

Pirfenidone-induced photoallergic reaction in a patient with idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic, fatal lung disease associated with inevitable loss of lung function. The prognosis is poor, with a median survival of 2.5-3.5 years afte...

Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis is one of the most common entities of the family of disorders known as the interstitial lung diseases. It is a chronic, progressive, and often-fatal disease with a median...

Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.

In glaucoma surgery, fibrotic processes occur, leading to impairment of liquid outflow. Activated fibroblasts are responsible for postoperative scarring. The transforming growth factor-β (TGF-β) pat...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement